These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 6217454)

  • 21. New drug evaluations: moxalactam (Moxam, Eli Lilly).
    Polk RE
    Drug Intell Clin Pharm; 1982 Feb; 16(2):104-12. PubMed ID: 6210519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Moxalactam in pediatrics.
    Barson WJ; Nahata MC
    Drug Intell Clin Pharm; 1982 Feb; 16(2):113-4. PubMed ID: 6210520
    [No Abstract]   [Full Text] [Related]  

  • 23. Past and current roles for cephalosporin antibiotics in treatment of meningitis. Emphasis on use in gram-negative bacillary meningitis.
    Landesman SH; Corrado ML; Shah PM; Armengaud M; Barza M; Cherubin CE
    Am J Med; 1981 Oct; 71(4):693-703. PubMed ID: 6269429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis.
    Schaad UB; McCracken GH; Loock CA; Thomas ML
    J Infect Dis; 1981 Feb; 143(2):156-63. PubMed ID: 6260870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Moxalactam in the treatment of intraabdominal sepsis and other surgical infections.
    Busuttil RW; McGrattan MA; Winston DJ
    Rev Infect Dis; 1982; 4 Suppl():S676-82. PubMed ID: 6218582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical evaluation of 6059-S in children, particularly in the treatment of bacterial meningitis (author's transl)].
    Kobayashi Y; Haruta T; Kuroki S; Okura K; Fujiwara T; Morikawa Y
    Jpn J Antibiot; 1981 Apr; 34(4):587-98. PubMed ID: 6457167
    [No Abstract]   [Full Text] [Related]  

  • 27. Use of moxalactam for bacterial meningitis.
    Kaplan SL; Mason EO; Feigin RD
    J Pediatr; 1982 May; 100(5):843. PubMed ID: 6461736
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of 18 cases of purulent meningitis with moxalactam. Pharmacokinetic data].
    Modai J; Vittecoq D; Decazes JM; Wolff M; Meulemans A
    Presse Med; 1983 Jan; 12(3):139-42. PubMed ID: 6220351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New concepts in the management of infants and children with meningitis.
    McCracken GH
    Pediatr Infect Dis; 1983; 2(3 Suppl):S51-5. PubMed ID: 6306611
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical evaluation of moxalactam in the treatment of respiratory tract infections, hepatobiliary infections, and septicemia.
    Saito A
    Rev Infect Dis; 1982; 4 Suppl():S623-8. PubMed ID: 6218575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Study of cefamandole in neonatal purulent meningitis caused by E. coli (author's transl)].
    Yamamoto T; Hirata S; Yokoi Y; Ohtani T; Hosoe A; Nishimura Y
    Jpn J Antibiot; 1981 Oct; 34(10):1410-5. PubMed ID: 7038185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Penetration of moxalactam into CSF.
    Landesman SH
    J Pediatr; 1982 Jul; 101(1):160-1. PubMed ID: 6211532
    [No Abstract]   [Full Text] [Related]  

  • 33. A comparative evaluation of moxalactam: antimicrobial activity, pharmacokinetics, adverse reactions, and clinical efficacy.
    Fitzpatrick BJ; Standiford HC
    Pharmacotherapy; 1982; 2(4):197-212. PubMed ID: 6221237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical evaluation of moxalactam].
    Acar JF
    Sem Hop; 1983 Jun; 59(26):1990-3. PubMed ID: 6310793
    [No Abstract]   [Full Text] [Related]  

  • 35. [Neonatal meningitis: is the combination ampicillin-gentamycin obsolete?].
    Muytjens HL; Kollée LA
    Tijdschr Kindergeneeskd; 1985 Oct; 53(5):185-8. PubMed ID: 3911489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Septicemia and focal infection. Efficacy of moxalactam. Results of the cooperative study conducted in France].
    Carbon C
    Sem Hop; 1983 Jun; 59(26):1981-4. PubMed ID: 6310791
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacology and cerebrospinal fluid penetration of moxalactam in children and dosage recommendations.
    Kaplan SL; Mason EO; Kvernland SJ; Calaway EL; Feigin RD
    Rev Infect Dis; 1982; 4 Suppl():S597-602. PubMed ID: 6218570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Examination of gram-negative bacilli from meningitis patients who failed or relapsed on moxalactam therapy.
    Eng RH; Cherubin C; Smith SM; Buccini F
    Antimicrob Agents Chemother; 1984 Dec; 26(6):850-6. PubMed ID: 6395799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Third-generation cephalosporins: a critical evaluation.
    Barriere SL; Flaherty JF
    Clin Pharm; 1984; 3(4):351-73. PubMed ID: 6432420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The in vitro antibacterial activity of LY127935 (6059S), a novel 1-oxa-beta-lactam antibiotic.
    Warren CA; King BA; Shannon KP; Eykyn SJ; Phillips I
    J Antimicrob Chemother; 1980 Sep; 6(5):607-15. PubMed ID: 6447682
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.